336 related articles for article (PubMed ID: 21914448)
1. C-122, a novel antagonist of serotonin receptor 5-HT2B, prevents monocrotaline-induced pulmonary arterial hypertension in rats.
Zopf DA; das Neves LA; Nikula KJ; Huang J; Senese PB; Gralinski MR
Eur J Pharmacol; 2011 Nov; 670(1):195-203. PubMed ID: 21914448
[TBL] [Abstract][Full Text] [Related]
2. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.
Porvasnik SL; Germain S; Embury J; Gannon KS; Jacques V; Murray J; Byrne BJ; Shacham S; Al-Mousily F
J Pharmacol Exp Ther; 2010 Aug; 334(2):364-72. PubMed ID: 20430844
[TBL] [Abstract][Full Text] [Related]
3. Aspirin attenuates pulmonary arterial hypertension in rats by reducing plasma 5-hydroxytryptamine levels.
Shen L; Shen J; Pu J; He B
Cell Biochem Biophys; 2011 Sep; 61(1):23-31. PubMed ID: 21327581
[TBL] [Abstract][Full Text] [Related]
4. CPU0213, a non-selective ETA/ETB receptor antagonist, improves pulmonary arteriolar remodeling of monocrotaline-induced pulmonary hypertension in rats.
Cui B; Cheng YS; Dai DZ; Li N; Zhang TT; Dai Y
Clin Exp Pharmacol Physiol; 2009 Feb; 36(2):169-75. PubMed ID: 18986320
[TBL] [Abstract][Full Text] [Related]
5. RP5063, a novel, multimodal, serotonin receptor modulator, prevents monocrotaline-induced pulmonary arterial hypertension in rats.
Bhat L; Hawkinson J; Cantillon M; Reddy DG; Bhat SR; Laurent CE; Bouchard A; Biernat M; Salvail D
Eur J Pharmacol; 2017 Sep; 810():92-99. PubMed ID: 28577964
[TBL] [Abstract][Full Text] [Related]
6. Genistein, a phytoestrogen, attenuates monocrotaline-induced pulmonary hypertension.
Homma N; Morio Y; Takahashi H; Yamamoto A; Suzuki T; Sato K; Muramatsu M; Fukuchi Y
Respiration; 2006; 73(1):105-12. PubMed ID: 16432296
[TBL] [Abstract][Full Text] [Related]
7. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease.
Zhao YD; Courtman DW; Deng Y; Kugathasan L; Zhang Q; Stewart DJ
Circ Res; 2005 Mar; 96(4):442-50. PubMed ID: 15692087
[TBL] [Abstract][Full Text] [Related]
8. [Effects of rosuvastatin on monocrotaline-induced pulmonary artery hypertension in rats].
Li XL; Guan RJ; Xu QH; Wu ZY
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Mar; 39(3):247-53. PubMed ID: 21609531
[TBL] [Abstract][Full Text] [Related]
9. Sildenafil limits monocrotaline-induced pulmonary hypertension in rats through suppression of pulmonary vascular remodeling.
Yen CH; Leu S; Lin YC; Kao YH; Chang LT; Chua S; Fu M; Wu CJ; Sun CK; Yip HK
J Cardiovasc Pharmacol; 2010 Jun; 55(6):574-84. PubMed ID: 20224427
[TBL] [Abstract][Full Text] [Related]
10. Preventive effects of raloxifene, a selective estrogen receptor modulator, on monocrotaline-induced pulmonary hypertension in intact and ovariectomized female rats.
Nishida M; Hasegawa Y; Tanida I; Nakagawa E; Inaji H; Ohkita M; Matsumura Y
Eur J Pharmacol; 2009 Jul; 614(1-3):70-6. PubMed ID: 19379725
[TBL] [Abstract][Full Text] [Related]
11. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
Schäfer S; Ellinghaus P; Janssen W; Kramer F; Lustig K; Milting H; Kast R; Klein M
Cardiovasc Res; 2009 Apr; 82(1):30-9. PubMed ID: 19131365
[TBL] [Abstract][Full Text] [Related]
12. 2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension.
Tofovic SP; Zhang X; Jackson EK; Dacic S; Petrusevska G
Vascul Pharmacol; 2006 Dec; 45(6):358-67. PubMed ID: 16872912
[TBL] [Abstract][Full Text] [Related]
13. Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats.
Lu J; Shimpo H; Shimamoto A; Chong AJ; Hampton CR; Spring DJ; Yada M; Takao M; Onoda K; Yada I; Pohlman TH; Verrier ED
J Thorac Cardiovasc Surg; 2004 Dec; 128(6):850-9. PubMed ID: 15573069
[TBL] [Abstract][Full Text] [Related]
14. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
[TBL] [Abstract][Full Text] [Related]
15. Amlodipine prevents monocrotaline-induced pulmonary arterial hypertension and prolongs survival in rats independent of blood pressure lowering.
Mawatari E; Hongo M; Sakai A; Terasawa F; Takahashi M; Yazaki Y; Kinoshita O; Ikeda U
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):594-600. PubMed ID: 17581214
[TBL] [Abstract][Full Text] [Related]
16. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats.
Nishimura T; Faul JL; Berry GJ; Vaszar LT; Qiu D; Pearl RG; Kao PN
Am J Respir Crit Care Med; 2002 Nov; 166(10):1403-8. PubMed ID: 12406854
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib alleviates experimental pulmonary arterial hypertension.
Kim SY; Lee JH; Huh JW; Kim HJ; Park MK; Ro JY; Oh YM; Lee SD; Lee YS
Am J Respir Cell Mol Biol; 2012 Nov; 47(5):698-708. PubMed ID: 22842494
[TBL] [Abstract][Full Text] [Related]
18. [Role of leukotriene B4 in monocrotaline-induced pulmonary hypertension].
Tabata T; Ono S; Song C; Noda M; Suzuki S; Tanita T; Fujimura S
Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Feb; 35(2):160-6. PubMed ID: 9103852
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model.
Bhat L; Hawkinson J; Cantillon M; Reddy DG; Bhat SR; Laurent CE; Bouchard A; Biernat M; Salvail D
Eur J Pharmacol; 2018 May; 827():159-166. PubMed ID: 29453947
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of FGFR Signaling With PD173074 Ameliorates Monocrotaline-induced Pulmonary Arterial Hypertension and Rescues BMPR-II Expression.
Zheng Y; Ma H; Hu E; Huang Z; Cheng X; Xiong C
J Cardiovasc Pharmacol; 2015 Nov; 66(5):504-14. PubMed ID: 26535780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
